Results 71 to 80 of about 2,524 (195)

The Impact of Nirsevimab on the Transport of Critically Ill Children

Children
Purpose: Respiratory syncytial virus-positive bronchiolitis continues to be the main diagnosis prompting transportation in children younger than one year of age. It represents approximately 15–20% of all services performed by a specialized pediatric transport team.
Carme Alejandre, Enrique Pazos, Pablo Gonzalez-Alvarez, Mònica Girona-Alarcón, Nuria Millán, Manuel Rodriguez, Aina Covas, Aina Martinez Planas, Elisabeth Esteban   +8 more
openaire   +4 more sources

Systematic Review: Efficacy, Safety Profile, and Cost-Effectiveness of Nirsevimab Versus Palivizumab for RSV Prevention in Children Under 24 Months

Children
Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTI) in infants and young children, with significant morbidity, hospitalizations, and healthcare costs.
Andreea Văduva, Alexandru Dinulescu, Anca Cristina Drăgănescu, Sorin Claudiu Man, Doina Anca Pleșca   +4 more
doaj   +1 more source

Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations

JAMA Pediatrics
Importance Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants and young children, imposing a substantial burden on health care systems. Nirsevimab, a long-acting monoclonal antibody, has shown high efficacy in clinical trials, and modeling studies suggest it ...
Attaianese, Federica, Carreras, Giulia, Trapani, Sandra, Alberti, Ilaria, Aricò, Maurizio, Attanasi, Marina, Bertolucci, Giulia, Bressan, Silvia, Caselli, Désirée, Casotto, Veronica, Cazzato, Salvatore, Chiarelli, Francesco, Felici, Enrico, Frusciante, Anna, Galeone, Maria Antonia, Garazzino, Silvia, Giannattasio, Antonietta, Gitto, Eloisa, Guerriero, Antonio, Guida, Fiorentina, Iudica, Giovanna, Lanari, Marcello, Mandato, Claudia, Manzini, Alice, Martelli, Gaia, Milani, Gregorio Paolo, Moriondo, Maria, Notarangelo, Lucia Dora, Nunziata, Felice, Pellegrino, Roberta, Peroni, Diego, Piccotti, Emanuela, Ponticiello, Eduardo, Ricci, Silvia, Rulli, Immacolata, Savoia, Fabio, Silvestro, Erika, Sisto, Antonella, Soro, Federica, Tonetto, Stefania, Zago, Alessandro, Dani, Carlo, Azzari, Chiara, Indolfi, Giuseppe   +43 more
openaire   +6 more sources

Cost-effectiveness of strategies using preventive interventions to protect infants in Chile from respiratory syncytial virus

Expert Review of Vaccines
Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract illness (LRTI; RSV-LRTI) among infants in Chile; young infants and infants born prematurely are at greatest risk.Research design and methods A cohort model was ...
Rafael Bolanos, Rafael Araos, Cecilia Gonzalez, Dino Sepulveda, Juan Francisco Falconi, Ahuva Averin, Mark Atwood, Erin Quinn, Amy W. Law, Diana Mendes   +9 more
doaj   +1 more source

Sociodemographic Factors, Intent-Uptake Disparities, and Nirsevimab Availability in Infant RSV Immunoprophylaxis

Pediatric Reports
Background/Objectives: Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and infant hospitalization in the US. RSV prevention evolved in 2023 as nirsevimab and maternal RSV pre-fusion vaccine became available for healthy ...
Brody J. Lipsett, Benjamin N. Fogel, Katherine E. Shedlock, Ian M. Paul, Eric W. Schaefer, Ruth E. Gardner, Leah D. Kaye, Steven D. Hicks   +7 more
doaj   +1 more source

Efficacy of nirsevimab for the prevention of RSV disease in infants: A systematic review, meta-analysis of randomized controlled trials, and global perspectives on recommendations and unmet needs

Pediatrics and Neonatology
Background: Respiratory syncytial virus (RSV) is a major cause of infant hospitalizations, with limited prophylactic options historically available.
Hsin-Chweng Lien, Chi-Hone Lien, Tzu-Yu Liu, Shun-Long Weng, Yu-Lin Tai, Ya-Ning Huang, Hsin Chi, Nan-Chang Chiu, Chun-Yan Yeung, Chien-Yu Lin   +9 more
doaj   +1 more source

Single-dose nirsevimab prevents RSV infection [PDF]

The Journal of Pediatrics, 2021
Shabir A, Madhi, Eric A F, Simões
openaire   +2 more sources

Nirsevimab Treatment of RSV Bronchiolitis in Pediatric Emergency Departments

New resistant mutations of respiratory syncytial virus type B (RSV-B) have been observed during the first year of implementation nirsevimab treatment. During the second season of implementation of nirsevimab treatment in France, RSV-B was predominant. To
De Mari, Pauline, Perceval, Lise Martin, Launay, Elise, Ouldali, Naim, Basmaci, Romain, Perceval, Lise, Martin, Aupiais, Camille, Rybak, Alexis, Cohen, Laure, de Pontual, Loic, Cohen, Robert, Lenglart, Lea, Levy, Corinne, Levieux, Karine, Béchet, Stéphane, Kramer, Rolf   +15 more
core   +1 more source

Cost-Effectiveness of Alternative Immunization Strategies to Protect Infants Against Respiratory Syncytial Virus in Germany: A Decision Modeling Study

Infectious Diseases and Therapy
Introduction Germany’s Standing Committee on Vaccination (STIKO) recommends the use of monoclonal antibody nirsevimab for infants in their first respiratory syncytial virus (RSV) season; however, incorporating RSVpreF maternal vaccination may protect ...
Caroline Lade, Erin Quinn, Lea J. Bayer, Amy W. Law, Christof von Eiff, Julia Schiffner-Rohe, Mark Atwood, Bennet Huebbe, Ahuva Averin   +8 more
doaj   +1 more source

Comparative Effectiveness of Monoclonal Antibody Prophylaxis for Preventing Severe Respiratory Syncytial Virus Infection in Infants: A Network Meta-Analysis

Journal of Clinical Question
Introduction: Respiratory syncytial virus (RSV) is a leading cause of LRTI and hospitalization in infants and young children. Passive immunization with monoclonal antibodies represents a major strategy for RSV prevention.
Tetsuya Nosho, Yukiho Otsu, Miri Nomura, Yumeng Zhang   +3 more
doaj   +1 more source